China issued updated rules for stem cell clinical trials, offering researchers a clear path for trial approvals while threatening clinics that offer unapproved stem cell treatments; the management of Shenzhen's Mindray Medical lowered its take-private offer for the medical device maker by 10% to $27 per ADS; DaVita Healthcare, a US owner/operator of dialysis clinics, formed a renal JV with Shunjing Renal Hospital in Shandong province; Yabao Pharma established a collaboration with the University of South Australia in Adelaide to develop new cancer drugs; and DelMar Pharma, a Canada-US company, together with its China partner, Guangxi Wuzhou Pharma, announced a China Phase IV trial of an approved cancer drug in refractory NSCLC.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
